Drug-drug interactions between canagliflozin , a sodium glucose co-transporter @ inhibitor approved for the management of type-@ diabetes mellitus , and an oral contraceptive ( OC ) , warfarin , and digoxin were evaluated in three phase @ studies in healthy participants .